RAF inhibitor re-challenge therapy in BRAF-aberrant pan-cancers: the RE-RAFFLE study.

Autor: Nelson BE; Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX, USA. benelson1@mdanderson.org., Roszik J; Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Ahmed J; Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Barretto CMN; Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Nardo M; Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Campbell E; Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Johnson AM; Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Piha-Paul SA; Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Oliva ICG; Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Weathers SP; Department of Neuro-Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Cabanillas M; Department of Endocrinology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Javle M; Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Meric-Bernstam F; Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Subbiah V; Early-Phase Drug Development, Sarah Cannon Research Institute, Nashville, TN, USA. Vivek.Subbiah@scri.com.

Publikováno v: Molecular cancer [Mol Cancer] 2024 Mar 26; Vol. 23 (1), pp. 64. Date of Electronic Publication: 2024 Mar 26.